NuCana plc (NASDAQ:NCNA) Short Interest Update

NuCana plc (NASDAQ:NCNA) was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 17,700 shares, a drop of 66.9% from the January 31st total of 53,500 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 123,500 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Schonfeld Strategic Advisors LLC bought a new position in NuCana during the 4th quarter valued at $54,000. Virtu Financial LLC purchased a new stake in shares of NuCana in the fourth quarter valued at about $48,000. Citadel Advisors LLC purchased a new stake in shares of NuCana in the fourth quarter valued at about $30,000. Finally, Two Sigma Securities LLC bought a new position in shares of NuCana during the fourth quarter valued at about $25,000. Institutional investors own 44.00% of the company’s stock.

NuCana Trading Down 1.3 %

Shares of NCNA stock opened at $0.93 on Friday. NuCana has a 12 month low of $0.85 and a 12 month high of $19.41. The firm has a market capitalization of $2.45 million, a PE ratio of -0.09 and a beta of 0.96. The firm has a fifty day simple moving average of $1.10 and a two-hundred day simple moving average of $2.12.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings results on Monday, November 25th. The company reported ($2.28) earnings per share for the quarter, beating the consensus estimate of ($3.49) by $1.21. On average, equities analysts predict that NuCana will post -13.42 earnings per share for the current fiscal year.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.